We are live on ! Find out more
GTHX

G1 Therapeutics, Inc. Common Stock
GTHX

Delisted

GTHX was delisted on the 17th of September, 2024.

Back to rankings

104 hedge funds and large institutions have $287M invested in G1 Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 42 increasing their positions, 18 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

193% more capital invested

Capital invested by funds: $98.2M → $287M (+$189M)

133% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 18

110% more call options, than puts

Call options by funds: $1.42M | Put options by funds: $676K

39% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 18

6% more funds holding

Funds holding: 98 → 104 (+6)

Holders
104
Holders Change
+6
Holders Change %
+6.12%
% of All Funds
1.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
42
Reduced
18
Closed
18
Calls
$1.42M
Puts
$676K
Net Calls
+$746K
Net Calls Change
+$444K

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$16.9M
2
PBA
Paradigm Biocapital Advisors
New York
+$10.1M
3
Fisher Asset Management
Fisher Asset Management
Washington
+$7.16M
4
Millennium Management
Millennium Management
New York
+$5.08M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$3.95M

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$17.4M
2
CA
CHI Advisors
New York
-$5.06M
3
Renaissance Technologies
Renaissance Technologies
New York
-$4.13M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$3.47M
5
Citadel Advisors
Citadel Advisors
Florida
-$2.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
Daiwa Securities Group
101
Daiwa Securities Group
Japan
$2K – – –
FCA
102
FinTrust Capital Advisors
South Carolina
$1K – – –
QC
103
Quent Capital
New York
$1K – – –
PA
104
Parallel Advisors
California
$1K +$571 +50 New
E
105
Ergoteles
New York
– -$1.09M -220,100 Closed
Federated Hermes
106
Federated Hermes
Pennsylvania
– -$887K -179,472 Closed
State of Wisconsin Investment Board
107
State of Wisconsin Investment Board
Wisconsin
– -$650K -131,600 Closed
KCM
108
Kennedy Capital Management
Missouri
– -$357K -72,347 Closed
Balyasny Asset Management
109
Balyasny Asset Management
Illinois
– -$140K -28,394 Closed
Ensign Peak Advisors
110
Ensign Peak Advisors
Utah
– -$125K -25,220 Closed
BCM
111
Bayesian Capital Management
New York
– -$118K -23,800 Closed
CANY
112
Caxton Associates (New York)
New York
– -$106K -21,388 Closed
HSBC Holdings
113
HSBC Holdings
United Kingdom
– -$87K -17,578 Closed
YIH
114
Y-Intercept (HK)
Hong Kong
– -$84K -17,100 Closed
BCA
115
Bay Colony Advisors
Massachusetts
– -$118K -14,195 Closed
LCM
116
Laurion Capital Management
New York
– -$63K -12,656 Closed
CC
117
Centiva Capital
New York
– -$58K -11,737 Closed
GG
118
Golden Green
South Carolina
– -$55K -11,220 Closed
Envestnet Asset Management
119
Envestnet Asset Management
Illinois
– -$53K -10,772 Closed
HNWAG
120
High Net Worth Advisory Group
Florida
– -$5K -1,000 Closed
New York State Common Retirement Fund
121
New York State Common Retirement Fund
New York
– -$1K -266 Closed
1 2 3 4
5

GTHX Hedge Fund Activity: Q3 2022 in Review

104 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q3 2022, worth a combined $287M — up 193% from $98.2M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new GTHX positions and 18 closed out — a net gain of 7 holders — while 42 added to existing stakes and 18 trimmed.

The largest buyer was State Street, adding an estimated $16.9M. The largest seller was Woodline Partners, cutting an estimated $17.4M.

  • 104 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q3 2022, up from 98 in Q2 2022.
  • Funds reported $287M of G1 Therapeutics, Inc. Common Stock stock for Q3 2022, up 193% quarter-over-quarter.
  • 25 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q3 2022 and 18 closed out, a net change of +7 holders.
  • The largest G1 Therapeutics, Inc. Common Stock buyer in Q3 2022 was State Street, an estimated $16.9M added.
  • The largest G1 Therapeutics, Inc. Common Stock seller in Q3 2022 was Woodline Partners, an estimated $17.4M sold.

Based on aggregated 13F filings for Q3 2022.